Non-coding RNAs (ncRNAs) are a heterogeneous group of transcripts that, by definition, are
not translated into proteins. Since their discovery, ncRNAs have emerged as important …

Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

Background Randomized trials of venetoclax plus anti-CD20 antibodies as first-line
treatment in fit patients (ie, those with a low burden of coexisting conditions) with advanced …

Background The combination of ibrutinib and venetoclax has been shown to improve
outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with …

Background GLOW is a phase 3 trial evaluating the efficacy and safety of ibrutinib-
venetoclax in older patients and/or those with comorbidities with previously untreated …

CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged≤ 70 years
with previously untreated chronic lymphocytic leukemia (CLL). Results from the cohort …

Abstract The MURANO trial (A Study to Evaluate the Benefit of Venetoclax Plus Rituximab
Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory …

The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine …

Background In the GLOW study, fixed-duration ibrutinib–venetoclax showed superior
progression-free survival versus chlorambucil–obinutuzumab in patients with previously …

Background The treatment landscape for chronic lymphocytic leukemia (CLL) continues to
undergo considerable evolution. Optimal selection of initial therapy from multiple effective …